Clinical trials
Phase 3 Wound Infection trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
24 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2004 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2010 | 4 |
| 2011 | 3 |
| 2012 | 2 |
| 2014 | 2 |
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
| Recruiting | 4 |
| Terminated | 3 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Durata Therapeutics Inc., an affiliate of Allergan plc | 3 |
| Pfizer | 3 |
| Major Extremity Trauma Research Consortium | 2 |
| Melinta Therapeutics, Inc. | 2 |
| Assiut University | 1 |
| Barretos Cancer Hospital | 1 |
| Bayer | 1 |
| Hospital General Universitario Elche | 1 |
| Massachusetts General Hospital | 1 |
| Memorial University of Newfoundland | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Wound Infection | 24 |
| Cellulitis | 8 |
| Abscess | 7 |
| Surgical Wound Infection | 7 |
| Postoperative Complications | 4 |
| Infections | 3 |
| Abdominal Abscess | 2 |
| Bacterial Infections | 2 |
| Soft Tissue Infections | 2 |
| Acute Kidney Injury | 1 |
Trials
Showing 26 to 24 of 24. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.